Characteristics and risk factors of retinal vasculopathy in antiphospholipid syndrome

被引:1
|
作者
Xie, Zhijuan [1 ]
Li, Hui [2 ,3 ]
Qi, Wanting [1 ]
Li, Jing [1 ,2 ,4 ]
Wu, Chanyuan [1 ,2 ,4 ]
Hu, Chaojun [1 ,2 ,4 ]
Jiang, Nan [1 ,2 ,4 ]
Wang, Qian [1 ,2 ,4 ,5 ]
Tian, Xinping [1 ,2 ,4 ,5 ]
Li, Mengtao [1 ,2 ,4 ,5 ]
Zhao, Jiuliang [1 ,2 ,4 ,5 ]
Sui, Ruifang [2 ,3 ]
Zeng, Xiaofeng [1 ,2 ,4 ,5 ]
机构
[1] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Rheumatol & Clin Immunol, Beijing, Peoples R China
[2] Peking Union Med Coll Hosp, State Key Lab Complex Severe & Rare Dis, Beijing, Peoples R China
[3] Chinese Acad Med Sci & Peking Union Med Coll, Peking Union Med Coll Hosp, Dept Ophthalmol, Beijing, Peoples R China
[4] Minist Sci & Technol, Natl Clin Res Ctr Dermatol & Immunol Dis NCRC DID, Beijing, Peoples R China
[5] Minist Educ, Key Lab Rheumatol & Clin Immunol, Beijing, Peoples R China
关键词
Antiphospholipid syndrome; retinal vasculopathy; risk factor; thrombotic microangiopathy; VEIN OCCLUSION; SYNDROME NEPHROPATHY; ARTERY; INVOLVEMENT; CLASSIFICATION; THROMBOSIS; CRITERIA;
D O I
10.1177/09612033211069762
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background Retinal vasculopathy including retinal artery occlusion (RAO) or retinal vein occlusion (RVO) was recently found to occur more frequently in antiphospholipid syndrome (APS) patients than non-APS patients. This study aims to investigate the clinical manifestation and risk factors of retinal vasculopathy among APS patients. Methods In this single-center prospective cohort study, we evaluated APS patients with or without retinal vasculopathy during 2018-2020 at Peking Union Medical College Hospital. Clinical variables were compared, and a logistical regression model was built to explore risk factors. Hierarchical cluster analysis using Euclidean distances was applied to identify clusters of variables. Results A total of 310 APS patients (67.4% female, mean age 38.1 years) were included, of whom 18 (5.8%) were diagnosed with retinal vasculopathy (9 with RVO and 9 with RAO). No significant differences were found among most demographic characteristics, clinical manifestations, or antibody profiles. APS-related heart valve disease (odds ratio OR 13.66, 95% confidence interval CI 4.55-40.98), APS nephropathy (OR 12.77, 95% CI 4.04-40.35), and thrombocytopenia (OR 2.63, 95% CI 1.01-6.89) were predictive of retinal vasculopathy. APS-related heart valve disease and nephropathy were also found to be statistically significant predictors in multivariate logistical regression analysis. Non-criteria manifestations were aggregated with retinal vasculopathy from a cluster analysis of variables. Conclusion Patients with APS-related heart valve disease and nephropathy suffered a higher risk of retinal vasculopathy. The underlying mechanisms of aPL-associated retinal vasculopathy may involve thrombotic microangiopathy, leading to poor prognosis and therapeutic changes.
引用
收藏
页码:178 / 186
页数:9
相关论文
共 50 条
  • [21] Antiphospholipid syndrome: An update on risk factors for pregnancy outcome
    De Carolis, Sara
    Tabacco, Sara
    Rizzo, Francesca
    Giannini, Andrea
    Botta, Angela
    Salvi, Silvia
    Garufi, Cristina
    Panici, Pierluigi Benedetti
    Lanzone, Antonio
    AUTOIMMUNITY REVIEWS, 2018, 17 (10) : 956 - 966
  • [22] Stroke and antiphospholipid syndrome-antiphospholipid antibodies are a risk factor for an ischemic cerebrovascular event
    Gaspersic, Natasa
    Zaletel, Marjan
    Kobal, Jan
    Zigon, Polona
    Cucnik, Sasa
    Semrl, Snezna Sodin
    Tomsic, Matija
    Ambrozic, Ales
    CLINICAL RHEUMATOLOGY, 2019, 38 (02) : 379 - 384
  • [23] Risk factors of first thrombosis in obstetric antiphospholipid syndrome
    Luo, Liang
    Cai, Qingmeng
    Liu, Xiangjun
    Hou, Yuke
    Li, Chun
    LUPUS SCIENCE & MEDICINE, 2024, 11 (01):
  • [24] Clinical characteristics and risk factors of microvascular involvement in primary antiphospholipid syndrome: a longitudinal single-center study in China
    Sun, Y.
    Zhao, J.
    Zhang, P.
    Wu, C.
    Jiang, N.
    Zhou, J.
    Zhang, S.
    Wu, Q.
    Wang, Q.
    Li, M.
    Zeng, X.
    LUPUS, 2019, 28 (13) : 1558 - 1565
  • [25] Clinical-Pathological Characteristics of Renal Injuries Identify Different Clusters in Patients With Antiphospholipid Antibodies
    Sciascia, Savino
    Yazdany, Jinoos
    Moroni, Gabriella
    Becker, Jan Ulrich
    Seshan, Surya V.
    Andrade, Danieli
    Emmi, Giacomo
    Cuadrado, Maria J.
    Radin, Massimo
    Cecchi, Irene
    De Simone, Emanuele
    Barreca, Antonella
    Caroti, Leonardo
    Innocenti, Samantha
    Fenoglio, Roberta
    Roccatello, Dario
    KIDNEY INTERNATIONAL REPORTS, 2023, 8 (04): : 754 - 763
  • [26] Thrombotic microangiopathy and the antiphospholipid syndrome
    Johnsen, S. J. A.
    Valborgland, T.
    Gudlaugsson, E.
    Bostad, L.
    Omdal, R.
    LUPUS, 2010, 19 (13) : 1569 - 1572
  • [27] Renal Involvement in Antiphospholipid Syndrome
    Pons-Estel, Guillermo J.
    Cervera, Ricard
    CURRENT RHEUMATOLOGY REPORTS, 2014, 16 (02)
  • [28] The impact of the search for thrombophilia risk factors among antiphospholipid syndrome patients with thrombosis
    Torresan, M
    Machado, TFGS
    Siqueira, LH
    Ozelo, MC
    Arruda, VR
    Annichino-Bizzacchi, JM
    BLOOD COAGULATION & FIBRINOLYSIS, 2000, 11 (07) : 679 - 682
  • [29] Impact of Classical Risk Factors for Arterial or Venous Thrombosis in Patients With Antiphospholipid Syndrome
    Navarro-Carpentieri, Daniel
    del Carmen Castillo-Hernandez, Maria
    Majluf-Cruz, Karim
    Espejo-Godinez, Guillermo
    Carmona-Olvera, Paola
    Moreno-Hernandez, Manuel
    Lugo-Garcia, Yolanda
    Hernandez-Juarez, Jesus
    Loarca-Pina, Luis
    Isordia-Salas, Irma
    Majluf-Cruz, Abraham
    CLINICAL AND APPLIED THROMBOSIS-HEMOSTASIS, 2018, 24 (05) : 834 - 840
  • [30] Chronic thromboembolic pulmonary hypertension in patients with antiphospholipid syndrome: Risk factors and management
    Rosen, Keren
    Raanani, Ehud
    Kogan, Alexander
    Kenet, Gili
    Misgav, Mudi
    Lubetsky, Aharon
    Niznik, Stanely
    Schafers, Hans-Joachim
    Segel, Michael J.
    Agmon-Levin, Nancy
    JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2022, 41 (02) : 208 - 216